Related Experiment Video
Updated: Mar 31, 2026

In Vitro Generation of Somite Derivatives from Human Induced Pluripotent Stem Cells
Published on: April 25, 2019
Regenerative medicine legislation in Japan for fast provision of cell therapy products
Y Fujita1, A Kawamoto1,2
1Unit of Regenerative Medicine, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation, Chuo-ku, Kobe, Japan.
Abstract:
A new legal framework consisting of three laws for cell-based and tissue-based therapies went into effect in November 2014 in Japan. Among the provisions of the laws, the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act) allows conditional and time-limited approval for regenerative medical products based on the ensured safety and estimated efficacy in small-scale clinical trials. The new legislation is expected to accelerate safe and fast provision of the innovative products to patients with intractable diseases.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
EPS and iPS Cells in Disease Research
iPS Cell Differentiation
Gene Therapy
Tissue Renewal without Stem Cells
However, failure of such a system...
Somatic to iPS Cell Reprogramming

